“raising our EPS guidance range to $5.45 to $5.60”

In context

“comparable sales growth can be found on Page 2 of our press release issued earlier today. And a reconciliation table containing the data needed to calculate comparable sales for growth can be found on pages 16 and 17. With that, I will now turn the call over to Robert Ford. Robert Ford: Okay. Mike, good morning, everyone, and thank you for joining us. Today, we issued second quarter results that included sales growth of 4.8% which represents an acceleration compared to the previous 2 quarters. And adjusted earnings per share of $1.31 which exceeded the midpoint of our guidance range and the consensus estimate, Considering our second quarter results, and updated outlook for the remainder of the year, we are reaffirming our full year guidance for comparable sales growth of 6.5% to 7.5% and raising our EPS guidance range to $5.45 to $5.60 Before summarizing our second quarter results, I want to highlight a few recent pipeline achievements, including completing patient enrollment in our tectonic coronary IVL pivotal trial, completing our FDA submission for approval of our new Amulet 360 left atrial appendage device obtaining CE Mark for Libre Duo the world's first dual glucose ketone monitoring sensor designed to detect rising ketone levels and help prevent diabetic ketoacidosis. We anticipate launching these 3 new products. Along with our Tactiflex Duo PFA catheter in the US at a steady cadence over the next 12 months. We also remain on track to begin patient enrollment in the fourth quarter for several important clinical trials that will support a steady cadence of future product launches. And these include a balloon expa”